|Articles|September 13, 2010

FDA on CV Risk in Diabetics

The FDA Guidance released in 2008 offers industry insight to why evaluation of heart risk in clinical trials is necessary.

ICE E-14 Step 2

Guidance for Industry

Integrated Cardiovascular Safety

Early Accuracy in New Drug Safety Analysis

Cardiac Safety: The Merits of ECG Centralization

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

FDA on CV Risk in Diabetics

Related Content

2026 DIA Global Annual Meeting: Why Federated Learning Reduces Friction

Real-Time Clinical Trial Oversight and the Infrastructure Gap: Q&A with Raj Indupuri, eClinical Solutions

Applied Clinical Trials at the 2026 DIA Global Annual Meeting: Conversations on Data, Outsourcing, and the Patient Voice

Accelerating patient recruitment: Connecting the right patients to the right trial

6 Ways Lab Data Can Improve Clinical Trials

Trending on Applied Clinical Trials Online

ACT Brief: Bridging Site-Sponsor Data Gaps, Major Study Retraction, and TNBC First-Line Approval

ACT Brief: DIA Leadership Amid Uncertainty, Reimagining CRO Contracts, and Eli Lilly Expansion

Nature Medicine Retracts Viral Lung Cancer Timing Study After Four-Month Investigation

ACT Brief: Operation TrialBlazer Launched, Protocol Complexity Rising, and Data Infrastructure for AI

Beyond Revenue Recognition: Rethinking CRO Contracting Through the CURED Shared Performance Contract